Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 394

The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.

Triple-negative breast cancer: is there a treatment on the horizon?

Open access
Yao, Hui, He, Guangchun, Yan, Shichao, Chen, Chao, Song, Liujiang, Rosol, Thomas J., Deng, Xiyun·2017·Oncotarget

Abstract

// Hui Yao 1 , Guangchun He 1 , Shichao Yan 1 , Chao Chen 1 , Liujiang Song 2 , Thomas J. Rosol 3 and Xiyun Deng 1 1 Department of Pathology, Hunan Normal University Medical College, Changsha, Hunan, China 2 Department of Pediatrics, Hunan Normal University Medical College, Changsha, Hunan, China 3 Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA Correspondence to: Xiyun Deng, email: // Keywords : breast cancer, triple-negative, therapeutics Received : May 12, 2016 Accepted : September 17, 2016 Published : September 27, 2016 Abstract Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast cancers, does not express estrogen receptor (ER) or progesterone receptor (PR) and lacks human epidermal growth factor receptor 2 (HER2) overexpression or amplification. These tumors have a more aggressive phenotype and a poorer prognosis due to the high propensity for metastatic progression and absence of specific targeted treatments. Patients with TNBC do not benefit from hormonal or trastuzumab-based targeted therapies because of the loss of target receptors. Although these patients respond to chemotherapeutic agents such as taxanes and anthracyclines better than other subtypes of breast cancer, prognosis remains poor. A group of targeted therapies under investigation showed favorable results in TNBC, especially in cancers with BRCA mutation. The lipid-lowering statins (3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors), including lovastatin and simvastatin, have been shown to preferentially target TNBC compared with non-TNBC. These statins hold great promise for the management of TNBC. Only with the understanding of the molecular basis for the preference of statins for TNBC and more investigations in clinical trials can they be reformulated into a clinically approved drug against TNBC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.12284

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 394

Metadata

Authors
Yao, H., He, G., Yan, S., Chen, C., Song, L., Rosol, T. J., & Deng, X.
Venue
Oncotarget
Published
2016-09-27
Volume
8
Issue
1
Pages
1913-1924
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2523763608
Cited by
394
References
87
FWCI
10.55
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.